Making gender visible: A path to systemic inclusion
As companies abandon efforts to promote inclusion, Boston Common’s Geeta Aiyer urges investors to keep it a top priority
As companies abandon efforts to promote inclusion, Boston Common’s Geeta Aiyer urges investors to keep it a top priority
Previously a no-go area, the firm has developed a drug pricing checklist
GSK’s VP of sustainability writes exclusively for ESG Clarity on the health benefits of investing in nature
EdenTree’s Patel says industry’s response to Covid and innovation keep it attractive to ESG investors
Access to medicine as well as litigation and reputation risks make it a complex area for sustainable investors
Access to medicine as well as litigation and reputation risks make it a complex area for sustainable investors
Access to medicine as well as litigation risks and reputation make it a complex area
Refinitiv’s annual index shows diversity and inclusion progress stalled in some areas despite it rising up the agenda
As much as 50% of prescription drugs are based on a molecule that occurs naturally in a plant
Whether it be energy, pharmaceuticals or industrials, businesses are focusing on sustainable future income streams, R&M’s Dan Hanbury tells ESG Clarity
Investment in antibiotics has slowed to a historically low rate, according to the first Planet Papers from Rathbones
Amati fund manager shares her home office set-up, looking after her health and her daughters’ flight home from Kenya during lockdown